Ursodeoxycholic 酸通过 JAK-STAT1 信号通路对抗 TGEV 感染
Zhiwei Sun1, Aobo Liu1, Yi Zhong1
1College of Veterinary Medicine, Southwest University, Chongqing, China.
Veterinary microbiology
|March 10, 2026
概括
乌尔索多西胆酸 (UDCA) 对猪的传染性胃肠炎病毒 (TGEV) 显示出强大的抗病毒作用. 这种胆汁酸降低病毒载量,提高小猪的生存率,并激活TGEV防御的关键免疫路径.
科学领域:
- 兽医病毒学 兽医病毒学
- 免疫学 免疫学 免疫学
- 药物发现 药物发现 药物发现
背景情况:
- 传染性胃肠炎病毒 (TGEV) 在猪业中造成重大经济损失,原因是小猪的死亡率高.
- 目前对TGEV的治疗方法有限,需要开发新的抗病毒药物.
- 作为胆汁酸的乌尔索多西胆酸 (UDCA) 已显示出对其他病毒的抗病毒性质.
研究的目的:
- 调查UDCA对TGEV的抗病毒活性.
- 阐明UDCA在对抗TGEV感染中的作用机制.
主要方法:
- 使用IPEC-J2细胞和TGEV (米勒菌株) 的体外研究.
- 分子技术包括西方Blot,qPCR和免疫光检测 (IFA).
- 负染色电子显微镜,体内小猪实验和转录组分析.
主要成果:
- UDCA显著降低了TGEV N基因拷贝数,蛋白质水平,病毒载量和受感染细胞中的核转位.
- 电子显微镜显示UDCA破坏了TGEV粒子的完整性.
- 在体内研究表明,UDCA缓解了TGEV症状,改善了小猪的生存率.
- UDCA通过JAK-STAT1通路激活TLR3-IRF3信号轴,诱导IFN-λ3,并通过JAK-STAT1通路调节ISG.
结论:
- UDCA对TGEV米勒菌株表现出显著的抗病毒功效.
- UDCA的机制涉及激活先天性免疫通路,包括TLR3-IRF3和JAK-STAT1,导致干扰素的产生和ISG上调.
- 乌迪卡代表了一种有前途的治疗候选药物,用于管理猪体TGEV感染.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
585
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
585
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
629
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
629
01:29Inflammatory Bowel Disease IV: Pharmacological Management
883
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
883
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
688
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
688
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
1.8K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
1.8K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
592
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
592